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Abstract
Background: The non-signalling chemokine receptors, including receptors DARC, D6 and CCX-CKR, have recently
been shown to be involved in chemokine clearance and activity regulation. The human chemokine receptor CRAM
(also known as HCR or CCRL2) is the most recently identified member of this atypical group. CRAM is expressed on
B cells in a maturation-stage dependent manner and absent on T cells. We have recently shown that it
competitively binds CCL19. CCL19 and its signalling receptor CCR7 are critical components involved in cell
recruitment to secondary lymphoid organs and in maturation. B cell Chronic Lymphocytic Leukemia (B-CLL) is a
low-grade lymphoma characterized by proliferative centres (or pseudofollicles). Proliferative centres develop due to
abnormal cellular localisation and they are involved in the development of malignant cells. CCR7 is highly
expressed on B cells from CLL patients and mediates migration towards its ligands CCL19 and CCL21, while CRAM
expression and potential interferences with CCR7 are yet to be characterized.
Results: In this study, we show that B cells from patients with B-CLL present highly variable degrees of CRAM
expression in contrast to more consistently high levels of CCR7. We investigated the hypothesis that, similar to the
atypical receptor DARC, CRAM can modulate chemokine availability and/or efficacy, resulting in the regulation of
cellular activation. We found that a high level of CRAM expression was detrimental to efficient chemotaxis with
CCL19. MAP-kinase phosphorylation and intracellular calcium release induced by CCL19 were also altered by CRAM
expression. In addition, we demonstrate that CRAM-induced regulation of CCL19 signalling is maintained over time.
Conclusions: We postulate that CRAM is a factor involved in the fine tuning/control of CCR7/CCL19 mediated
responses. This regulation could be critical to the pivotal role of CCL19 induced formation of proliferation centres
supporting the T/B cells encounter as well as disease progression in B-CLL.
Background
B cell Chronic Lymphocytic Leukemia (CLL) is the most
frequent adult low-grade lymphoproliferative disorder
with a highly variable course, characterized by the accu-
mulation of a specific subset of B cells in the bone mar-
row, blood, and lymphoid tissue. B-CLL patients
typically present with proliferation centres or pseudofol-
licles in secondary lymphoid organs and are characteris-
tic of CLL amongst all the other B-cell malignancies.
They favour a microenvironment where dividing malig-
nant cells are in contact with T-cells and cytokines that
nurture the proliferation of malignant cells (for review
[1]). Chemokines and their receptors are expected to be
closely associated with the formation of these prolifera-
tive centres by directing cellular localisation and
interactions.
Chemokines orchestrating leukocyte trafficking and
localisation are required for cell maturation as well as
immune functions. Leukocytes undergo several stages of
migration from organs of production to blood stream
and later throughout their maturation and active time.
The chemokines CCL19 (formerly ELC, MIP3-ß) and
CCL21 (SLC, 6Ckine), by binding to their receptor
CCR7, play a role in regulating the homing of mature
DCs, and subsets of T and B cells to lymph nodes.
Close contact between cellular subsets within lymph
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will eventually mature into different effector subtypes
(reviewed in [2]). CCR7 stimulation by CCL19 or
CCL21 has recently been shown to result in MAP-
kinase phosphorylation and this is likely to be involved
in CLL cell survival [3]. CCL19 and CCL21, although
activating the same receptor, are distinct in several
features. For example, CCL21 is structurally prone to
high affinity for glycosaminoglycans (GAGs) due to a
C-terminal basic tail [4], whereas CCL19 is one of the
chemokines with the lowest affinity for GAGs known to
date [5,6]. In addition, interactions with CCR7 have dif-
ferent cellular outcomes for each chemokine. Binding of
CCL19 to CCR7 results in internalization and degrada-
tion of CCL19 and receptor desensitization. Conversely,
after ligation of CCR7 by CCL21, the receptor remains
stable at the cell surface and its signalling capacity is
l i m i t e d[ 7 , 8 ] .I th a sa l s ob e e ns h o w nt h a tw h i l eC C L 2 1
is produced at its site of action by fibroblastic reticular
cells of the T cell zone and HEVs (High Endothelial
Venules), CCL19 expression is restricted to non-
endothelial cells in the T cell zone of secondary lym-
phoid organs and thus needs to be translocated to the
HEVs [9]. Besides binding to CCR7, CCL19 and CCL21
both bind with high affinity to another member of the
atypical chemokine receptor family: CCX-CKR [10,11].
This scavenger receptor efficiently regulates CCL19/21
bioavailability by degradation. However, CCL19/21 both
avoid regulation by the two best characterized atypical
receptors D6 and the Duffy antigen receptor for chemo-
kines (DARC). While D6 is an effective scavenger of
many inflammatory chemokines [12,13], DARC has
been shown to be a key player in the transcytosis of
CCL2 and CXCL8 from their production site in the tis-
sue to the luminal side of the endothelium [14].
We have recently shown that a third CCL19 binding
chemokine receptor exists: CRAM (also known as HCR
or CCRL2). Encoded by the gene CCRL2, it is expressed
on B cells in a maturation-stage dependent manner [15].
Besides CCL19, CRAM also binds the inflammatory che-
mokine CCL5 (RANTES) and the adipokine chemerin,
while CCL21 fails to efficiently displace radiolabelled-
CCL19 binding [16,17]. Ligand interaction does not
induce any classical signalling response; instead CRAM
displays a constitutive and clathrin-dependent cycling
activity, resulting in the internalization of CCL19. Based
on these results and the fact that CRAM has a modified
version of the usually highly conserved DRY motif in its
sequence (a feature of non-signalling chemokine recep-
tors) we previously presented that CRAM is a silent, aty-
pical receptor.
In this study, we investigated the role of CRAM in
B-CLL, analysing CCL19 induced activation and found
that CRAM is an efficient modulator of CCR7-CCL19
cellular responses.
Results
CCR7 and CRAM expression on lymphocytes
In a previous publication we had shown CRAM to be
highly expressed in pro- and pre-B primary cells as well
as in corresponding cell lines [15]. The characterization
of CRAM and CCR7 expression at the surface of cell
lines and primary B cells from healthy donor controls
was completed in the present study. MEC-1 (a B-CLL
derived cell line) showed high expressions of both recep-
tors whilst Nalm6 (pre-B Acute Lymphoblastic Leukemia
derived cell line) and Reh (Acute Lymphoblastic Leuke-
mia) cells had a similar level of CRAM but no CCR7
(Figure 1A). The expression of both CRAM and CCR7 at
the surface of B cells from different healthy controls was
shown to be consistent (Figure 1B and [18]). In parallel,
the expression of CCR7 and CRAM was investigated at
the surface of B cells from 23 CLL patients. Whilst CCR7
had a high but limited range of expression level (Figure 2A,
data not shown and [3]), CRAM expression level was
considerably more variable with regard to geometric
mean fluorescence values, ranging from 2 to 949 (Figure
2A and data not shown).
CRAM expression is associated with a reduction in CCL19
induced migration
The apparent inconsistency of CRAM expression in
B-CLL led us to investigate the potential consequences
for CCL19 induced migration. Two B-CLL primary cells
samples paired for their similar levels of CCR7 yet vari-
able levels of CRAM were selected (Figure 2A) and
tested for their capacity to respond to CCL19 induced
chemotaxis. A higher expression of CRAM was asso-
ciated with a lower efficacy of chemotaxis (Figure 2A).
To further investigate this observation, migrated cells
from the lower wells of chemotaxis chambers, after
migration towards CCL19 or CCL21, were stained for
CRAM and CCR7 (Figure 2B). The CCR7 level of
expression was not altered on the migrated cells. How-
ever, CCL19-induced migration was associated with a
lowered expression of CRAM, not observed for CCL21.
This observation is the result of cell selection rather
than of receptor down-regulation as CCL19 does not
induce CRAM internalization (CRAM constitutively
recycles in a ligand independent manner [16]). Impor-
tantly, neither CCL19 nor CCL21 interfered with CRAM
detection by the antibody used in the previous experi-
ment (Figure 2B, lower right histogram). High levels of
CRAM reduce the ability of cells to migrate toward
CCL19, whereas it is not important for migration to
CCL21 under the same conditions.
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to CCL21
MEC-1 cells express both CRAM and the classical recep-
tor for CCL19: CCR7 (also the classical receptor for
CCL21) and were used to investigate MAPK phosphoryla-
tion after stimulation by CCL19 or CCL21 (Figure 3A). To
evaluate the implications of CRAM expression on CCR7
activity, we blocked CRAM functions utilising different
methods and analyzed the effects on CCL19 induced
CCR7 activation. As phosphorylation of p44/42 has been
s h o w nt ob ei n v o l v e di nC C R 7i n d u c e dBc e l la c t i v a t i o n
[19-21], we examined phosphorylation in the absence or
presence of CRAM blocking antibodies. Addition of
CRAM specific antibody potentiated the CCL19 triggered
response. Furthermore, CRAM-antibody induces a longer
signalling profile suggesting that CRAM could be involved
Figure 1 FACS analysis of chemokine receptor expression on different cell types. A. The histograms show the relative fluorescence
intensity of the cells stained with anti-CRAM or anti-CCR7 antibody (black line) compared with the corresponding isotype control (tinted
histogram). Nalm6 and Reh cells are positive for CRAM and negative for CCR7. MEC-1 cells are positive for both CRAM and CCR7. The additional
histogram for MEC-1 cells shows the down-regulation of CRAM expression by siRNA transfection (light grey solid histogram). B. Mean
fluorescence intensity (MFI) of CRAM and CCR7 of 4 healthy controls (HC). Isotype control has been repeated for each assay, the mean + SD of
the four fluorescence geometric means is shown as a reference.
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specificity of this observation, a similar experiment was
conducted using CCL21 instead of CCL19. The antibody-
induced potentiation of MAPK phosphorylation was not
observed with this chemokine (Figure 3A). Similar results
were obtained in chemotaxis assays (Figure 3B). The addi-
tion of the isotype control antibody did not alter the che-
motactic profile of CCL19 or CCL21. However addition of
antibodies against CRAM enhanced chemotaxis toward
CCL19 but not toward CCL21.
To support these observations, experiments were con-
ducted without blocking antibodies and in a different
pathway of activation. CRAM expression was down-
regulated by siRNA transfection in MEC-1 cells, and
chemotaxis assays were performed using CCL19 or
CCL21. siRNA achieved a CRAM down-regulation of
approximately 30% (Figure 1A), low albeit sufficient to
effect chemotaxis (Figure 4A). CRAM down-regulation
resulted in enhanced CCL19 mediated chemotaxis but
did not affect CCL21 induced chemotaxis of MEC-1
cells. This suggests that CRAM regulates CCL19 and
thereby CCR7 activation, probably by competition either
of ligand binding or by modifying/influencing activation.
Finally, we obtained concurring results in an additional
MEC-1 (CRAM
+/CCR7
+) chemotaxis assay. In this
experiment, CRAM was blocked with its alternative
ligands: chemerin and CCL5 (Figure 4B). Addition
of CCL5 to the upper part of the chemotaxis well
Figure 2 Efficiency of CCL19 induced chemotaxis of B-CLL cells is independent of the expression level of CCR7 but not of CRAM.
A. The two upper panels depict CCR7 and CRAM expression at the surface of B cells from 4 patients with B-CLL (B-CLL1 to 4). Out of 23 patients
tested, we selected two isolates of samples with similar levels of CCR7 and highly variable CRAM, and MEC-1 cells are shown as a reference. Results
shown are MFI from a single flow cytometry experiment for the patients’ samples; isotype control was repeated for each of them and represented
as the mean of the 5 experiments + SD. The lowest panel depicts the mean + SD of chemotaxis toward 200 ng/ml CCL19 (one experiment done in
triplicate). B. CCR7 and CRAM expression were tested at the surface of MEC-1 cells after migration induced by 200 ng/ml CCL19 or CCL21 and
compared with the level of expression of cells before migration (control). A significantly lower CRAM expression is observed on cells that have
migrated to CCL19 (unpaired T-test, p = 0.0007). The histograms below the graph depict one representative experiment, showing lowered CRAM
expression in cells moving toward CCL19 (blue) but unaltered CRAM expression in similar experimental conditions with CCL21 (green). No
alteration of CCR7 level of expression is observed (middle histogram). Incubation of MEC-1 cells with either CCL19 or CCL21 does not alter the
detection of CRAM by the antibody used for the previous experiments (right histogram, one representative experiment).
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Page 4 of 12significantly increased the migration toward CCL19, yet
this did not modify migration toward CCL21. This
observation suggests that addition of CCL5 was not
responsible per se for this increased migration but that
there was a cooperative effect with CCL19. CCL5 addi-
tion was tested at two concentrations (CCL5-High: 50
ng/ml and CCL5-Low: 5 ng/ml) which showed signifi-
cant decreases of chemotaxis (p = 0.005 and 0.048
respectively). Chemerin addition also resulted in signifi-
cantly enhanced migration toward CCL19, but only the
highest dose tested (Chem-High: 500 ng/ml) was statis-
tically significant (p = 0.032). As low levels of RNA
from classical receptors for chemerin and CCL25
(respectively ChemR23 and CCR9) and proteins from
CCR5 and CCX-CKR were detected in MEC-1 cells
(Additional file 1, Figure S1), we proceeded to conduct
additional chemotaxis controls. CCL5 (for CCR5 expres-
sion), chemerin (for ChemR23) and CCL25 (for CCR9
and CCX-CKR) influences on the MEC-1 migration
capacity were defined by assessing chemotaxis (Figure 5A)
or chemokinesis (Figure 5B). None of these assays showed
any conclusive involvement of CCL5, CCL25 or chemerin
in MEC-1 migratory behaviour. No significant alteration
of CCL19-induced migration was observed with CCL25,
indicating that there was no involvement of CCX-CKR in
our observations (Figure 4B). In addition, we controlled
Figure 3 CCR7 activation by CCL19 but not CCL21 is increased by anti-CRAM blocking antibody. A. MEC-1 cells were incubated with 10
ng/ml CCL19 (left) or 10 ng/ml CCL21 (right) in the presence of an anti-CRAM antibody or of relevant isotype control for the indicated periods
of time. Addition of anti-CRAM antibody increased the phosphorylation of MAPK p44/42. Upper panels show western blot results of
phosphorylated or control p44/42, lower panels depict the quantification of five and three independent similar experiments for CCL19 and
CCL21, respectively. The intensity of each phosphorylated p44/42 band has been normalised to the corresponding unstimulated control, and the
result expressed in function of the time 0 point for isotype control for each experiment. Mean + SD are depicted, unpaired T-test analysis results
in significant p values for 10 and 15 minute incubations with CCL19. No significance was observed with CCL21. B. The potentiation of CCL19
induced response by anti-CRAM antibody was confirmed in a chemotaxis experiment, where MEC-1 cells were stimulated to migrate toward
CCL19 either in the presence of antibody against CRAM (light grey) or of corresponding isotype control (dark grey). CRAM antibody induced a
significant increase of migration toward CCL19 (unpaired T-test, p = 0.03). No changes were observed for similar experiments with CCL21 (data
from 3 independent experiments done in triplicate). C. Schematic illustration of molecular mechanisms explaining the previous results:
potentiation of CCL19 induced p44/42 phosphorylation by CRAM blockage.
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chemotaxis regulatory experiment with CCL21. CCL21
induced migration was not enhanced by the addition of
other CRAM ligands (Figure 4B). Overall these experi-
ments provide some insight into the nature of CRAM
involvement in CCR7 regulation, implying that CRAM
expression influences CCL19 activity and that this system
is affected by other factors, including other cytokines
(CCL5, chemerin).
CRAM regulation over time
Finally, we examined CRAM modulation of CCL19
availability over time and performed a calcium-release
assay. We stimulated MEC-1 (CRAM
+/CCR7
+)w i t h
Nalm6 (CRAM
+/CCR7
-) that had been pre-incubated
with chemokines; Nalm6 cells do not express CCX-
CKR, the previously described scavenger receptor for
CCL19 (Additional file 1, Figure S1) hence CCL19 regu-
lation observed cannot be attributed to it. Incubation of
the Nalm6 cells (CRAM
+/CCR7
-) was done at 37°C to
allow the internalisation of chemokines by CRAM and
they were subsequently washed thoroughly with PBS
buffer, before a further incubation (30 min) at 37°C or
4°C to allow or prevent respectively re-expression of
potentially internalized chemokines. Chemokine incu-
bated Nalm6 (CRAM
+/CCR7
-)w e r et h e na d d e dt o
MEC-1 cells (CRAM
+/CCR7
+) to investigate whether
calcium release could be induced from chemokines
Figure 4 Potentiation of CCL19, but not CCL21 induced chemotaxis by CRAM blockage. A. Upper panel: MEC-1 cells (CRAM
+/CCR7
+) were
used to do a chemotaxis assay toward 200 ng/ml CCL19 or CCL21, 48 h after transfection with negative control siRNA (black) or CCRL2 siRNA
(grey). Experiment was carried out 5 times in triplicate, data shown are means + SD and statistical analysis were done by Mann-Whitney U-test,
all chemotaxis indexes reached significance when compared with migration toward buffer (p ≤ 0.05): potentiation of CCL19, but not CCL21
induced chemotaxis by CRAM down-regulation. B. Upper panel: Chemotaxis migration toward CCL19 was done adding inert CRAM ligands in
the upper part of the well CCL5 (H = 50 ng/ml, L = 5 ng/ml) and chemerin (H = 500 ng/ml, L = 50 ng/ml) or CCL25 as a control of exclusion
for CCX-CKR involvement in the effect observed. Experiments were carried out 3 times in triplicate. Data shown are means + SD and analysis
using Mann-Whitney U-test, all chemotaxis indexes reach significance when compared with migration toward buffer (P ≤ 0.001). Lower panel: as
a CRAM specificity control, similar experiments were done, this time toward CCL21, for the conditions where significant changes were observed
with CCL19. Neither CCL5-L nor chem-H altered the chemotaxis induced by CCL21. C. Schematic illustration of molecular mechanisms illustrating
the previous results: potentiation of CCL19, but not CCL21 induced chemotaxis by CRAM blockage by competitors or reduced level of
expression of the receptor.
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6A). Nalm6 cells that were incubated at 4°C post wash
induced a smaller calcium release in MEC-1 cells, upon
coincubation at 37°C, relative to control, unwashwed
Nalm6 cells. This indicates that all the chemokines used
in the first incubation step were not available for stimu-
lation of MEC-1 cells (CRAM
+/CCR7
+)a n dt h e r e f o r e
were not presented at the cell surface. MEC-1 cells co-
incubated with Nalm6 cells, previously incubated at
37°C, had induced calcium release; almost as intense as
before washing and significantly higher than stimulation
by 4°C incubated Nalm6 cells. This implies that a pro-
portion of CCL19, that was internalized in Nalm6 cells
during the first incubation period, was available for
MEC-1 stimulation during co-incubation in this experi-
mental setting (Figure 6D). In comparison with CCL21,
no difference was seen when Nalm6 cells were incu-
bated at 37°C versus 4°C, supporting the involvement of
a CCL19 specific receptor. Additionally, we monitored
the CCL19-Nalm6 induced calcium release in MEC-1
cells after the two temperature conditions of initial
exposure of the Nalm6 cells to the chemokine (4°C or
37°C) followed by a washing step and variable time and
temperature conditions for the second incubation step
(Figure 6B). This setting allows the monitoring of the
internalization of CCL19 by Nalm6 (CRAM
+/CCR7
-)
over time. When cells are initially incubated at 4°C, only
surface bound CCL19 is present at the beginning of the
experiment. Further incubation at 37°C did not change
this observation, implying that the amount of chemo-
kine associated with Nalm6 (CRAM
+/CCR7
-)a n da v a i l -
able for stimulation of MEC-1 (CRAM
+/CCR7
+)i s
sustained (blue trace). Nalm6 cells were incubated at
37°C prior to the washing step, to allow CCL19 to be
internalized. This created two different pools of chemo-
kine: one present at the cell surface and one intracellu-
lar. The latter would only be available to stimulate
MEC-1 (CRAM
+/CCR7
+) when re-expressed at the cell
surface and if CRAM is efficiently recycling rather than
degrading CCL19; a 37°C dependent process. A correla-
tion between incubation time and calcium release inten-
sity was observed with enhanced responses when the
second incubation period is done at 37°C. This resulted
in CCL19 cell surface re-expression (purple and red
traces). Quantification of CCL19 by ELISA was used to
ascertain the location of the chemokines in suspension
with Nalm6 cells after the longest incubation time (90
min). Three fractions were separated: supernatant, cell
surface associated or internalized (Figure 6C). CCL19
associated to cells incubated first at 4°C and then at 37°
C was found at lower concentrations than in the two
other incubation conditions, with a very low proportion
of CCL19 internalized and/or associated with the cells
surfaces. CCL19 associated to the Nalm6 cells in the
two other incubation conditions (preliminary incubation
at 37°C followed by a washing step and further incuba-
tion at 4°C or 37°C) and presented higher concentra-
tions of CCL19, with a similar quantity of CCL19 either
associated to the cell surface or released in the superna-
tant (sum of blue and pink bars). However, when both
primary and secondary incubations are at 37°C, the pro-
portion of CCL19 in the cells or associated to the cell
surface is increased, probably supporting signalling over
time, an observation already seen in Figure 3. These
data provide support to our hypothesis of CRAM invol-
vement in active regulation of circulating CCL19.
Figure 5 MEC-1 mobility in presence of CRAM and CCX-CKR ligands. A. CRAM ligands CCL5 (50 ng/ml) and chemerin (50 ng/ml) did not
induce cellular migration by themselves; CCL25 (100 ng/ml), a control ligand to exclude CCX-CKR involvement in our observations, was also not
able to induce MEC-1 chemotaxis, CCL19 (100 ng/ml) was used as a positive control (2 independent experiments done in triplicate. Data shown
are means + SD, analysed using Mann-Whitney U-test). B. Absence of chemokinesis induction by the chemokines placed in the upper well or in
upper and lower wells (one experiment done in triplicate).
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CRAM has been described as a non-signalling receptor
for CCL5 and CCL19 by our group and for chemerin by
Zabel et al. [16,17]. This study investigated the implica-
tion of ligand binding to CRAM on cellular activity in
the context of B-CLL. We demonstrate that CRAM
expression is involved in the regulation of chemokine
activity and we postulate that CRAM acts as a signal
hub, capable not only of controlling circulating chemo-
kines but also the activity of the corresponding classical
chemokine receptors.
Following Comerford et al.’sh y p o t h e s i so nt h ei n v o l -
vement of CCX-CKR in the alteration of circulating
level of chemokine levels, we demonstrate here that
CRAM modifies CCL19 availability and distribution and
investigated the consequences of such scavenging on the
functions of this chemokine [10]. Direct competition for
CCL19 might be involved in this mechanism, but in
light of the much higher affinity of CCL19 for CCR7
than for CRAM, additional inhibitory mechanisms are
expected. For example, interference with efficient cou-
pling of CCR7 to beta-arrestin is likely to be implicated.
Arrestin involvement in CRAM internalization has
indeed been shown by our group [16]. Arrestin-3 has
also been shown to be involved in CCR7 internalization
after stimulation by CCL19 but not by CCL21 [22]. The
importance of arrestins in chemokine receptor internali-
zation has been reviewed by Luttrell and Lefkowitz [23],
Figure 6 Induction of calcium release by CRAM presented chemokines. MEC-1 cells (CRAM
+/CCR7
+) were loaded with fluo-3/AM and then
stimulated by Nalm6 cells (CRAM
+/CCR7
-) pre-incubated with CCL19 or CCL21 (100 ng/ml) for 30 min at 37°C and then treated as mentioned
on the graph x axis. A. Calcium release was monitored by flow cytometry, allowing the discrimination between Nalm6 and MEC-1 cells,
according to their SSC/FSC characteristics (Additional file 2, Figure S2). Spots represent results in arbitrary units from individual experiments and
mean values of the five independent experiments are depicted as a line. Statistical analyses were done performing a T-test. B. Same
experimental settings but this time changing the temperature of the initial incubation step (4°C: blue line, 37°C: pink and red lines), and the
length of second incubation as indicated at various temperatures (4°C: pink line, 37°C blue and red lines). After incubations at different
temperatures, the calcium release experiments were done at 37°C. C. Localisation of CCL19 in the cellular suspension used to induce the calcium
release of MEC-1 cells was done using ELISA. Cells treated in the same way than for calcium experiments were used to quantify CCL19 in the
supernatant (blue), at the cellular surface (pink) or internalised (green). When kept at 37°C throughout the experiments, the proportion of CCL19
internalized into the cells is higher, suggesting a possible time associated regulation of CCL19 by CRAM. D. Schematic illustration of molecular
mechanisms explaining the previous results: incubation at 4°C blocks the internalisation of CRAM and hence its ability to sustain a CCL19
induced answer over time.
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tion on chemokine receptor activity have been summar-
ized by Neel et al. [24]. The internalization of chemokine
receptors is mainly seen as a desensitization mechanism
and hence a way to interrupt and regulate signalling.
However, for chemotaxis and calcium release, which are
both mechanisms that need to be sustained over
time, impaired internalization has been shown to be
unfavourable. Our results indicate a regulation mechan-
ism involving CCR7 receptor localisation at the cell
surface, rather than internalization itself, at least as a first
step. Variability in the CCR7 internalization scheme
[7,8], as described for CCL19 and CCL21, could be a
result of this preliminary modification of receptor locali-
sation; however additional experimental evidence is
required to confirm this hypothesis. When expressed on
the surface of different cell types, CRAM might compete
for binding of CCL19 with CCR7, but would then favour
later CCL19 presentation to CCR7 expressing cells and
cell surface accumulation, via CRAM, as suggested by
our calcium release experiments (Figure 6).
When compared with other atypical receptor func-
tions, CRAM’s functions appear to be similar to
DARC’s, which has been shown to be a circulating-
chemokine- “buffering” receptor [25] as well as a carrier
of chemokines across endothelial cells. Thus far, we
have assumed CRAM to be a narrow spectrum atypical
chemokine receptor, similar to what has been published
for CCX-CKR and its ligands: CCL19/21/25 [11,26]. It
seems remarkable to have a chemokine regulated by two
narrow spectrum atypical chemokine receptors when it
is not regulated by the two large spectrum ones (D6 and
DARC). The explanation for this observation is probably
to be found in the central roles of CCL19 in immune
cell maturation (T and B cells) and function (mature
DCs). Two major differences exist between CCX-CKR
and CRAM-mediated regulation of CCL19: first, the affi-
nity of CCX-CKR for CCL19 is much higher than
CRAMs. This does not necessarily reduce the impor-
tance of the role of CRAM in CCL19 regulation, as
complementary roles for signalling chemokine receptors
with different affinities has previously been described
and documented (eg. CXCR1-CXCR2 [27]). The second
major difference between these two atypical receptors is
that CCX-CKR also regulates CCL21, the only other
ligand for CCR7 [28], while we show in this article that
CRAM regulation of CCL21 was weak or even absent.
A differential role of CCL19 and CCL21 has already been
shown by their activation of receptor CCR7: stimulation
by CCL19, but not by CCL21, promotes CCR7 desensiti-
zation and CCL19 induces MAP-kinase phosphorylation
much more efficiently in CCR7 expressing cells than
CCL21, although both chemokines have similar affinities
for CCR7.
CRAM expression has been shown to be broad
[15,17,29], hence it could impact the chemokine regula-
tion in various pathophysiological processes. So far, the
most documented involvement of CRAM in pathology
is its up-regulation on polymorphonuclear (PMN) cells
during rheumatoid arthritis (RA) [29,30]. In this condi-
tion, the level of CCR7 expression is likewise up-regu-
lated at the surface of T cells (but unchanged at the
s u r f a c eo fP M N )a n dC C L 1 9s e c r e t e db ym a t u r eD C s
increased, emphasizing a thorough perturbation of
CCL19 activities [29-31]. At the time, CRAM was
shown to be up-regulated in RA, CCL19 was not known
to be one of its ligands, and hence the impact of its
expression had not been assessed directly. The modifica-
tion of chemokine receptor pattern is a common feature
of B cell-malignancies [32]. In B-CLL it appears that
CCR7 activity alteration is associated with the formation
of proliferative centres and lymphadenopathies [33]. We
present here the first evidence for CRAM involvement
in the regulation of B cell migration (Figure 2B, 3B and
4). In addition, we show that CRAM expression is also
associated with a reduced MAPK activation (Figure 3)
that is of particular interest when considering that che-
mokine induced MAPK phosphorylation is involved in
cell survival in B-CLL. These two characteristics (modu-
lation of migration and increased cell survival by
CCL19) are essential for the creation and maintenance
of proliferative centres in B-CLL and are supportive of
the concept of CCR7 antagonism as a therapeutic target
in B-CLL [34]. Furthermore, regulation of CCL19 by
CRAM may be involved in a broader range of lympho-
proliferative diseases. For example, a discrepancy
between CCR7 level of expression and CCL19 induced
chemotaxis has been shown for B cells in mantle cell
lymphoma [18], CCR7 expression is altered in primary
central nervous system lymphoma [35], and CCL19 is
also associated with resistance to apoptosis in B-cell
Acute Lymphocytic Leukemia [36]. In addition, CCR7
down-regulation is observed in T cell lymphomas when
compared with healthy tissue [37]. We show in vitro
that co-expression of CRAM interferes with the CCL19
induced activation of CCR7. Given the importance of
CCR7 in secondary lymphoid organ organisation (for
review [38]), its down-regulation, associated with an up-
regulation of CRAM, is likelyt ob ei n v o l v e di nT - c e l l
accumulation in secondary lymphoid organs by spatio-
temporal perturbation of cell localisation. Overall, our
results provide a new perspective for the molecular
mechanism supporting the development of these
malignancies.
Conclusions
We have presented new experimental data supporting
the hypothesis of CRAM functioning as an atypical
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activity and as an integrative hub for different cytokines
and receptors activities. We propose the hypothesis that
CRAM functions as a regulator of altered cell migration
in B-CLL.
Methods
Cell culture and reagents
All cell line media were supplemented with 10% Fœtal
Calf Serum (FCS) and 1% penicillin/streptomycin.
Nalm6 and Reh cells were maintained in RPMI and
MEC-1 cells in IMDM in a humidified atmosphere (5%
CO2) at 37°C (all from Invitrogen, Carlsbad, CA).
The murine monoclonal antibody against CRAM (anti-
HCR/CRAM-A/B, Clone 152254) was produced by R&D
Systems (Minneapolis, MN). The murine PE-labelled
monoclonal antibodies against CCR7 (MAB197), CCR1
(FAB145P), CCR3 (FAB155P) and CCR5 (FAB182P) were
purchased from R&D Systems. CCX-CKR (sc-46836)
unlabelled antibody was purchased from Santa Cruz
(Heidelberg, Germany). RPE-labelled rabbit anti-mouse
IgG was from DakoCytomation (Glostrup, Denmark),
Alexa-647 rabbit anti-goat (A21446) was from Invitro-
gen (Darmstadt, Germany) and chemokines were from
R&D systems (Minneapolis, MN). PBMCs from Buffy
coats of healthy donors were isolated by Ficoll density-
gradient centrifugation. For isolation of chronic
lymphocytic leukemia (CLL) cells, blood samples were
collected from patients after informed consent. Periph-
eral blood mononuclear cells were isolated by density
gradient centrifugation over Ficoll-Hypaque (Pharma-
cia, Uppsala, Sweden), and contained more than 90%
CLL B cells [15].
Flow cytometric detection of chemokine receptors
expression
5×1 0
6 cells were incubated with the appropriate anti-
bodies 30 min at 4°C in PBS, 0.5% BSA, and then
washed in the same buffer prior to incubation with the
secondary antibodies in the same conditions. After final
washes, cell fluorescence was assessed using a FACScali-
bur counting 2 × 10
4 cells. Flow cytometry data were
analysed with Flowjo.
Western blot evaluation of p44/42 phosphorylation
Cells were starved in FCS free medium for 2 h and sti-
mulated with chemokines for the indicated times at 37°
C. Protein lysates were prepared with 100 μll y s i sb u f f e r
(20 mM Tris/HCl pH 8.0, 150 mM KCl, 1 mM EDTA,
0.2 mM Na3VO4, 1% Triton X-100, 0.5 mM PMSF) with
protein inhibitor cocktail (complete®, Roche Applied
Science, Basel, Switzerland). Equal amounts of protein
were separated by 10% SDS polyacrylamide gel electro-
phoresis and transferred onto PVDF membranes.
Western blot analysis was performed using the appro-
priate antibodies recognizing the phosphorylated form
of p44/p42 or pan-protein antibodies (#9101 and #9102,
respectively) and were from Cell Signalling (Beverly,
MA). Immunoreactive bands were visualized using
horseradish peroxidase-conjugated secondary antibody
and the enhanced chemiluminescence system (GE
Amersham, Fairfield, CT). Densitometric quantification
was done using Adobe Photoshop (Adobe Photoshop
9.0, Adobe, San Jose, CA, 2005). Data are presented as
mean arbitrary density units normalized to the ratio
between phosphorylated proteins to non-phosphory-
lated forms at time 0 in presence of the control
isotype + SD. This statistical analysis as well as all the
following ones were performed using Graphpad prism
version 5.02.
siRNA knocking down of CRAM expression
Expression of CRAM was knocked down using siRNA
against the CRAM gene: CCRL2 (Santa Cruz, sc-77982,
Santa Cruz) and siPORT lipid siRNA transfection
reagent, following the manufacturer’s instructions and
using negative control siRNA when required (sc-37007).
Chemotaxis
Chemotaxis experiments were done using NeuroProbe
96 well plate devices with 5 μm pore filter (Receptor
Technologies, Warwickshire, UK). 50 μlo fa2×1 0
6
cell/ml suspension in HBSS, 0.1% BSA were loaded on
the upper part of the filter after filling up the lower part
with buffer (HBSS, 0.1% BSA) or chemokines in suspen-
sion in the same buffer. When stated, cellular suspen-
sion was completed with the indicated concentration of
chemokines or chemerin. Migration was done over 1.5
hours and cell number evaluated by resuspending the
migrated cells from the lower part of the well in 200 μl
buffer and counting them by flow cytometry for a fixed
period of time. The numbers of replicates and details of
statistical analyses are described in the figure legends.
Calcium release experiment
10
7/ml MEC-1 cells were incubated for 45 min at 37°C
in PBS buffer containing Fluo-3/AM probe at a final
concentration of 2 μM (Invitrogen Molecular Probes),
then washed and resuspended in calcium buffer (RPMI,
0.11 μMC a C l 2, 0.1% BSA) to a final concentration of
2×1 0
6cell/ml and incubated at 37°C for 5 min before
proceeding to the calcium release assay at 37°C. The cal-
cium release assay was performed by inducing MEC-1
with the addition of Nalm6 cells previously incubated
with CCL19 or CCL21 (100 ng/ml) at 37°C (Figure 6A)
or as indicated (Figure 6B). Nalm6 cells were then
washed 3 times at 4°C in 5 ml PBS, 0.1%BSA, and incu-
bated for a further 90 min in calcium buffer at 37°C
Catusse et al. Molecular Cancer 2010, 9:297
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used to induce calcium release in MEC-1 cells. Results
were monitored using a FACScalibur, FSC/SSC scatter-
ing allowing the differentiation between MEC-1 and
Nalm6 cells according to their physical characteristics
(Additional file 2, Figure S2).
ELISA
Nalm6 cells were incubated in 500 μlo fb i n d i n gb u f f e r
(RPMI, 20 mM HEPES, 0.1%BSA) with or without 100
ng/ml CCL19 for 30 minutes at 37°C or 4°C as indi-
cated. After this preliminaryi n c u b a t i o ns t e pt h e yw e r e
washed 3 times with 5 ml of PBS/0.1%BSA, and further
incubated at 37°C or 4°C, as indicated, for 90 minutes in
500 μl of binding buffer. Three different sample collec-
tions were done: supernatant (1), cell associated fraction
after a brief incubation of the cells with 50 μlo f
10xPBS, to disrupt interactions between chemokines
and their receptors (as described in [14]), and resuspen-
sion in a final volume of 500 μl PBS 1× for collection
(2), finally the cells were lysed by 200 μl lysis buffer
(20 mM Tris-HCl (pH 8.0), 150 mM KCl, 1 mM EDTA,
1m MN a 3VO4, 1 mM PMSF, 1% Triton X-100 and pro-
tease inhibitor mix) and resupended in a final volume of
500 μl with PBS (3). ELISAs were performed according
to the manufacturer’s instructions. Each fraction was
normalised to its equivalent fractions collected in
absence of CCL19.
RNA-extraction and reverse transcription-PCR
As described in [15], total RNA was isolated using the
RNeasy RNA isolation kit (Qiagen, Dusseldorf,
Germany) according to the manufacturer’si n s t r u c t i o n s .
Residual DNA was removed by DNase I Digestion
(Ambion, Austin, TX). The cDNA synthesis was per-
formed using 1 μg RNA as a template for oligo-dT
(12-18 mer) primers and 50 Units SuperScript II reverse
transcriptase (Super Script first-strand synthesis system
for reverse transcription (RT-) PCR; Invitrogen). The
cDNA was amplified using Taq polymerase (Qiagen).
The following primer pairs were used for PCR: CRAM-B:
5’-ATGGCCAATTACACGCTGGCACCAGAG-3’ and
the corresponding antisense primer 5’-CACTTC-
GGTGGAATGGTCAGGTTCTTCCCTC-3’,G A P D H :
the sense primer 5’-GGAGTCCACTGGCGTCTTCACC-
3’ and the antisense primer 5’-ATTGCTGATGATCTT-
GAGGCTGTTGTC-3’ CCR9: 5’-GCCCAGGCCAT-
GAGA-3’ and the corresponding antisense primer 5’-
AACCCACTGGGCCTGGCTGA-3’ and ChemR23: the
sense primer 5’-CCGGGACACAGCCAACCTGC-3’ and
the antisense primer 5’-CAGTGGCCAGGGGCAAAC-
CC-3’. Annealing was done at 60°C.
Additional material
Additional file 1: Chemokine receptor expressions at the surface of
the cells used in this article. CRAM expression was controlled by
RT-PCR on MEC-1, Nalm6, Reh and healthy control B cells. All cells were
shown to be positive for CRAM. CCR9 and ChemR23 were also assessed
for MEC-1 cells. Low expression levels were observed for both receptors.
In the lower panel, protein expression was investigated for CCR1, CCR3,
CCR5 and CCX-CKR in MEC-1 cells and CCX-CKR in Nalm6. A low
expression of CCR5 and CCX-CKR was observed on MEC-1 cells.
Additional file 2: Physical differences allowing discrimination
between Nalm6 and MEC-1 cells. FSC and SSC settings allow direct
discrimination by flow cytometry between Nalm6 cells and MEC-1 cells.
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